Trademarkia Logo

Canada

C$
Trademark Search in Canada
EVOLVE BIOLOGICS

View On IC.GC.CA

EVOLVE BIOLOGICS
REGISTERED

on 2 Jan 2020

TM5 Status

LIVE/REGISTRATION/Issued and Active

Your registration has been issued and is active. You can now use the TM5 mark.

Last Applicant/ Owned by

TBI Pharma Holdings Ltd.

181 Bay Street, Suite 4700P.O Box 792, Bay Wellington TowerBrookfield PlaceToronto

ONTARIO

CA

M5J2T3

Serial Number

1866274 filed on 3rd Nov 2017

Registration Number

TMA1067699 registered on 2th Jan 2020

Registration expiry Date

2th Jan 2030

Correspondent Address

SMART & BIGGAR LP

SCOTIA PLAZA40 KING STREET WEST40th FLOORTORONTO

ONTARIO

CA

M5H3Y2

EVOLVE BIOLOGICS

Trademark usage description

biologics from human blood, human blood plasma, fractionated human blood plasma, cryopaste, and cryoprecipitate for human clinical use, namely, plasma Read More

Classification Information

Class [005]
Biologics from human blood, human blood plasma, fractionated human blood plasma, cryopaste, and cryoprecipitate for human clinical use, namely, plasma protein fractions, serum albumin, immunoglobulins, coagulation factors, antihemophilic factors, clotting factors, enzymes, coenzymes, coactivators, inhibitors, and structural proteins; resins, namely, polysaccharide beads cross-linked to ligands for capturing proteins from human blood, human blood plasma, fractionated human blood plasma, cryopaste, and cryoprecipitate using chromatographic methods.

Classification kind code

11

Class [009]
Protein chromatography equipment for capturing biologics from human blood, human blood plasma, fractionated human blood plasma, cryopaste, and cryoprecipitate.

Classification kind code

11

Class [037]
Construction of biotech, biopharmaceutical and plasma manufacturing facilities relevant to the manufacturing of biologics from human blood, human blood plasma, fractionated human blood plasma, cryopaste, and cryoprecipitate; Consultancy in the field of biotech construction.

Classification kind code

11

Class [040]
Contract manufacturing services for others for biologics from human blood, human blood plasma, fractionated human blood plasma, cryopaste, and cryoprecipitate for research and development, and clinical use; Consultancy in the field of biotech manufacturing.

Classification kind code

11

Class [041]
Educational services, namely, designing, arranging, and conducting training programs for research and development of biotechnology, manufacturing of biologics, design, construction, and use of chromatography equipment.

Classification kind code

11

Class [042]
Development of pharmaceutical preparations and medicines, namely, development services for others for the capture of biologics from human blood, human blood plasma, fractionated human blood plasma, cryopaste, and cryoprecipitate for research and development; consulting services for others concerning the capture of biologics from human blood, human blood plasma, fractionated human blood plasma, cryopaste, and cryoprecipitate for research and development, design and construction of chromatography equipment, and design of biotech, biopharmaceutical and plasma manufacturing facilities, namely, scientific research and evaluation, and engineering; Design of biotech, biopharmaceutical and plasma manufacturing facilities relevant to the manufacturing of biologics from human blood, human blood plasma, fractionated human blood plasma, cryopaste, and cryoprecipitate.

Classification kind code

11

Mark Details

Serial Number

1866274

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 190
on 9th Oct 2019		Registration Pending
Submitted for opposition 191
on 9th Oct 2019		Registration Fee Notice Sent
Submitted for opposition 42
on 17th Jul 2019		Advertised
Submitted for opposition 26
on 27th Jun 2019		Approved
Submitted for opposition 27
on 9th May 2019		Approval Notice Sent
Submitted for opposition 22
on 2th Jan 2019		Search Recorded
Submitted for opposition 20
on 2th Jan 2019		Examiner's First Report
Submitted for opposition 1
on 6th Nov 2017		Created
Submitted for opposition 31
on 6th Nov 2017		Formalized
Submitted for opposition 30
on 3rd Nov 2017		Filed